The prognosis of patients with higher-risk myelodysplastic syndromes (MDS) remains poor despite available therapies. Histone deacetylase inhibitors have demonstrated activity in patients with MDS and in vitro synergy with azacitidine. METHODS: A phase 2 randomized, placebo-controlled clinical trial of azacitidine and pracinostat was conducted in patients who had International Prognostic Scoring System intermediate-2-risk or high-risk MDS. The primary endpoint was the complete response (CR) rate by cycle 6 of therapy. RESULTS: Of 102 randomized patients, there were 51 in the pracinostat group and 51 in the placebo group. The median age was 69 years. The CR rate by cycle 6 of therapy was 18% and 33% (P 5.07) in the pracinostat and placebo groups, respectively. No significant differences in overall survival (median, 16 vs 19 months, respectively; hazard ratio, 1.21; 95% confidence interval, 0.66-2.23) or progression-free survival (11 vs 9 months, respectively; hazard ratio, 0.82; 95% confidence interval, 0.546-1.46) were observed between groups. Grade 3 adverse events occurred more frequently in the pracinostat group (98% vs 74%), leading to more treatment discontinuations (20% vs 10%). CONCLUSIONS: The combination of azacitidine with pracinostat did not improve outcomes in patients with higher-risk MDS. Higher rates of treatment discontinuation may partially explain these results, suggesting alternative dosing and schedules to improve tolerability may be required to determine the potential of the combination. Cancer 2017;123:994
INTRODUCTION
Myelodysplastic syndromes (MDS) are a group of clonal disorders characterized by defective hematopoiesis, leading to cytopenias and the risk of transformation to acute myeloid leukemia (AML). 1 Patients with higher-risk disease based on prognostic scores derived from the International Prognostic Scoring System (IPSS) 1 and its recently revision (IPSS-R), 2 have a short overall survival (OS) and an increased risk of transformation to AML. Therapy with hypomethylating agents, such as azacitidine or decitabine, is the standard of care for these patients. Although it has been demonstrated that the use of these agents can improve the survival of patients with higher-risk MDS, [3] [4] [5] only 30% to 40% of patients achieve a significant response, and all eventually lose the response or die from their disease. Hypomethylating agent failure is associated with poor outcomes, with a median survival of only 4 to 6 months. [6] [7] [8] Aberrant promoter-region CpG island hypermethylation is associated with transcriptional silencing of tumorsuppressor genes, leading to leukemogenesis. 9 Deacetylated histones are usually associated with DNA hypermethylation and transcriptional repression. 10, 11 Inhibition of histone deacetylation and DNA hypermethylation can induce reexpression of silenced genes in leukemia in a synergistic fashion. 12 Preclinical data suggest that the combination of hypomethylating agents like azacitidine with histone deacetylase (HDAC) inhibitors potentially could be synergistic in vivo. 12, 13 Several clinical studies have explored these combinations in patients with MDS and AML. [14] [15] [16] Pracinostat, an HDAC inhibitor, has exhibited preclinical activity in myeloid malignancies. 17 An initial phase 2 exploratory study of pracinostat combined with azacitidine in 9 patients with IPSS intermediate-2 or high-risk MDS had an overall response rate (ORR) of 89% (8 of 9 patients), including 7 complete responses (CRs) plus CRs with incomplete count recovery and complete cytogenetic responses in 5 patients (56%), with an acceptable toxicity profile, which consisted mainly of grade 1 or 2 fatigue and nausea. 18 On the basis of these data, and with the hypothesis that the addition of pracinostat may be able to improve on the response rates of azacitidine, we designed a randomized, phase 2 study comparing azacitidine versus combination therapy with pracinostat in patients with newly diagnosed, higher-risk MDS.
MATERIALS AND METHODS
This study was registered at clinicaltrial.gov as NCT01873703. The study was approved by the institutional review board and ethics committees at each study site.
Patient Population
Patients aged 18 years who had a diagnosis of MDS according to the French-American-British or World Health Organization classification, had from 5% to 30% bone marrow blasts, and were classified with IPSS 1 intermediate-2-risk (1.5-2 points) or high-risk (2.5 points) MDS were eligible if they had an Eastern Cooperative Oncology Group performance status from 0 to 2, adequate renal and hepatic function (creatinine <2 mg/ dL or creatinine clearance 60 mL/minute, total bilirubin <1.5 times the upper limit of normal or 2 mg/dL, aspartate and alanine aminotransferase levels 2.5 times the upper limit of normal), and a QTcF interval 470 msec. A negative pregnancy test was required before enrollment. The main exclusion criteria were prior treatment with hypomethylating agents; prior MDS therapy consisting of chemotherapy, immunotherapy, or biologic or hormone therapy within the 21 days before the start of study therapy; or hydroxyurea within 48 hours before the start of study therapy. Other exclusion criteria included current, unstable arrhythmia requiring treatment; a history of symptomatic congestive heart failure (New York Heart Association class III or IV); a history of myocardial infarction within 6 months of enrollment or current unstable angina; clinical evidence of central nervous system involvement; inability to take oral medication; active infection with human immunodeficiency virus or chronic hepatitis B or C; any life-threatening illness unrelated to cancer; and the presence of a malignant disease within the last 12 months with the exception of adequately treated in situ carcinomas, basal or squamous cell carcinoma, or nonmelanoma skin cancer.
Study Design and Treatment
This was a randomized, double-blind, placebo-controlled study of pracinostat or placebo in combination with azacitidine. Patients were randomized at a 1:1 ratio to 1 of 2 groups: group 1 (experimental group) received pracinostat plus azacitidine, and group 2 (control group) received placebo plus azacitidine. The groups were stratified according to risk group (intermediate-2-risk vs high-risk MDS). The primary objective was a CR by cycle 6 of therapy. Response assessment was performed using the revised 2006 International Working Group (IWG) criteria. 19 Secondary objectives included the ORR, defined as a combined CR and partial response (PR); the clinical benefit rate, defined as combined hematologic improvement (HI), PR, bone marrow CR, and CR; HI rates; response duration (time from the initial determination of response to disease progression, relapse, or death on study); OS (time from the first day of study drug administration to death on study); progression-free survival (time from the first day of study drug administration [day 1] to disease progression or relapse according to IWG criteria or death on study); event-free survival (time from the first day of study drug administration to disease progression, relapse or failure according to IWG criteria, death on study, or discontinuation because of clinical progression or lack of efficacy); and the rate of leukemic transformation at 6, 12, 18, and 24 months. Dose adjustments and treatment discontinuations were based on hematologic and nonhematologic toxicity. Therapy could be held in the event of grade 3 nonhematologic toxicity or for patients with a baseline absolute neutrophil count 1 3 10 9 /L or platelets 30 3 10 9 /L who experienced a decrease >50% in 1 of these cell counts at day 28 and had a decrease <15% in baseline bone marrow cellularity on day 42 if platelets remained <30 3 10 9 /L, the absolute neutrophil count remained <1 3 10 9 /L, and bone marrow blasts were <5% at that time, respectively. A sample size of 100 patients was planned to provide reasonable power to detect a clinically important difference in the CR rate between the 2 groups.
Therapy and Follow-Up
Treatment consisted of azacitidine at a dose of 75 mg/m 2 daily intravenously or subcutaneously for 7 days (either on days 1-7 or on days 1-5, 8, and 9 of each cycle) in combination with oral pracinostat 60 mg (experimental group) or oral placebo 60 mg (control group) every other day for 3 days a week for the first 3 weeks of each cycle. Treatment cycles were repeated every 28 days unless there was a delay because of toxicity. Therapy was planned to continue until disease progression, patient request, or intolerable toxicity. Patients could receive standard-of-care supportive measures, such as antiemetics, blood transfusions, and antimicrobials. All patients were evaluated at baseline with bone marrow aspiration, including conventional cytogenetic assessment. Additional bone marrow biopsies and aspirates were performed at the end of cycles 2 and 6 in case there was evidence of disease progression or eligibility for allogeneic stem cell transplantation.
Statistical Considerations
The efficacy and safety analyses were conducted on the randomized and treated patients. The sample size was selected to provide reasonable power to detect a clinically relevant difference in CR rates. All P values were 2-sided, and P values <.05 were considered statistically significant. The Kaplan-Meier product-limit method 20 was used to estimate time-to-event variables. The effects of covariates were assessed using univariate and multivariate Cox proportional hazards models.
Safety
Safety was assessed by analyzing the reported incidence of treatment-emergent adverse events (AEs), AEs leading to withdrawal, and laboratory toxicities, and was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
RESULTS

Patient Characteristics
In total, 102 patients were enrolled in 19 US centers, randomized, and treated between June 2013 and August 2014, including 51 patients (50%) in the pracinostat group and 51 patients (50%) in the control group. Baseline demographics and disease characteristics are summarized in Table 1 . The groups were generally well balanced.
The median age across groups was 69 years (range, 26-90 years), and 69% (70 of 102 patients) were men. In total, 68 (67%) patients had intermediate-2-risk MDS, and 34 (33%) had high-risk MDS. Three patients had refractory anemia (RA), 1 had refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS), 49 had RA with excess blasts 2 (RAEB-2), 17 had RAEB-1, 3 had RAEB not specified, 11 had RA with excess blasts in transformation (RAEB-T), 8 had chronic myelomonocytic leukemia (CMML), 6 had refractory cytopenia with multilineage dysplasia (RCMD), 3 had MDS/myeloproliferative neoplasm unclassified (overlap syndrome), and 1 had MDS associated with isolated 5q deletion (del[5q]). Two patients (33%) with RCMD and the patient with MDS who had isolated del(5q) were considered higher-risk based on the presence of a complex karyotype. Median bone marrow blast percentages in patients with CMML were 15% (range, 6%-16%) and 11% (range, 2%-15%) in the pracinostat and placebo groups, respectively. Four patients who were randomized to the placebo group and were not eligible because of a diagnosis of RA or RA with ringed sideroblasts were treated and included in the analysis.
Disease Response
The CR rate by cycle 6, which was the study's primary endpoint, was 18% (9 of 51 patients) in the pracinostat group compared with 33% (17 of 51 patients) in the placebo group (P 5 .07). A single patient in the pracinostat group achieved a CR after cycle 6 ( Table 2) . Of the patients who were transfusion-dependent at baseline, 25% (2 of 8 patients) in the pracinostat group and 28% (2 of 7 patients) in the placebo group achieved transfusion independence. The cytogenetic response rate in the pracinostat group was 42% (14 of 33 patients) compared with 55% (17 of 31 patients) in the placebo group (P 5 .14). The HI rate was 35% (15 of 43 patients) and 55% (24 of 44 patients) in the pracinostat and placebo groups, respectively (P 5 .51). The overall clinical benefit rate (ie, CR 1 PR 1 HI 1 bone marrow CR) was 53% (27 of 51 patients) in the pracinostat group compared with 63% (32 of 51 patients) in the placebo group (P 5 .14). Table  2 summarizes all response data. The median response duration for the patients who achieved a clinical benefit was 12 months and 9 months in the pracinostat and placebo groups, respectively (hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.23-1.79) (Fig. 1) .
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Survival
The median duration of follow-up was 15 months. The median OS in the pracinostat and placebo groups was 16 and 19 months, respectively (HR, 1.21, 95% CI, 0.65-2.23) (Fig. 2) and the median PFS was 11 and 9 months (HR, 0.93; 95% CI, 0.49-1.75), respectively (Fig. 3) . The median event-free survival was 9 months in both groups (HR, 0.82; 95% CI, 0.46-1.46), and the 1-year OS rate was 60% in both groups. In total 15 deaths (15%) occurred during the study (pracinostat group, n 5 9 [18%]; placebo group, n 5 6 [12%]). In both treatment groups, the most common reason for Abbreviations: HI-E, HI with erythroid response, HI-N, with neutrophil response; HI-P, HI with platelet response.
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Cancer March 15, 2017 death on study was AEs, including febrile neutropenia and pneumonia, followed by disease progression. Mortality rates after 6 months of study discontinuation were 36.6% (15 of 40 patients) and 33.3% (17 of 51 patients) in the pracinostat and placebo groups, respectively. 
Safety
In total, 101 (99%) patients experienced at least 1 treatment-emergent AE. Drug-related AEs were reported in 49 patients (96%) in the pracinostat group and in 45 patients (88%) in the placebo group. The most frequently reported AEs for both groups are summarized in Table 3 . Generally, grade 3 AEs occurred more frequently in patients who were receiving pracinostat compared with those who were receiving placebo (98% vs 74%; P < .001), with fatigue (24% vs 0%), febrile neutropenia (33% vs 20%), and thrombocytopenia (47% vs 26%) the most common. There were 12 fatal AEs on study, including 7 (14%) on the pracinostat arm and 5 (9%) on the placebo arm. The most common fatal AE in the pracinostat group was febrile neutropenia in 2 patients, and pneumonia occurred in 2 patients in the placebo group. The 30-day and 60-day mortality rates were 6% and 8% in the pracinostat group and 4% and 6% in the placebo group. Treatment-related AEs leading to pracinostat or placebo dose-reductions occurred in 10% of patients in the pracinostat group and 6% of patients in the placebo group. Azacitidine dose reductions were required in 18% of patients in the pracinostat group compared with 6% in the placebo group. Discontinuation of pracinostat or placebo because of AEs was required in 20% and 10% of patients, respectively, with 2% patients in both groups requiring azacitidine discontinuation. More than twice the number of patients discontinued study drugs in the first courses of therapy in the pracinostat group compared with placebo group, including 17 (33%) versus 6 (12%) before the start of cycle 3 and 32 (63%) versus 16 (32%) before the start of cycle 5, respectively. Therefore, twothirds of patients discontinued study drugs before cycle 5 of therapy compared with one-third in the placebo group.
Exploratory Analysis
Because of the high rate of early discontinuations in the pracinostat group, we performed an ad hoc analysis to evaluate the efficacy of the combination in patients who could tolerate at least 4 cycles of. In total, 54 patients, including 19 (37%) in the pracinostat arm and 35 (69%) in the placebo arm, had started cycle 5 of therapy. No significant differences in terms of the CR rate after cycle 6 of therapy (42% vs 43%), the ORR (47% vs 43%), or the clinical benefit rate (95% vs 80%) were observed between the pracinostat and placebo groups, respectively. However, although the difference was not statistically significant, a numerically longer duration of response (median, 12 months vs 9 months) and OS (median, not reached vs 19 months) was observed in the pracinostat group.
DISCUSSION
Although available standard-of-care therapies like azacitidine have demonstrated an ability to improve the OS of patients with higher-risk MDS, [3] [4] [5] only a subset of patients responds to these treatments, and their prognosis after loss of response to therapy remains poor. [6] [7] [8] In the search for more effective regimens, and based on the synergistic results in preclinical models and the favorable results from an open-label, single-center study of azacitidine and pracinostat in previously treated patients with higher-risk MDS, 18 we conducted this multicenter, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of pracinostat combined with azacitidine in previously untreated, higher-risk MDS. In contrast to observations from the open-label study, the addition of pracinostat to azacitidine did not improve the rate of CRs, cytogenetic responses, or OS in the current study. Also, there were no benefits with the combination in other secondary survival endpoints, such as event-free or progression-free survival.
One possible explanation is poor tolerability, leading to shorter overall exposure to study therapies. Although the number of patients who experienced AEs was similar in both treatment groups, a higher proportion of patients who received combined pracinostat and azacitidine experienced grade 3 AEs, mainly fatigue, gastrointestinal symptoms, and myelosuppression, and these occurred predominantly during the first cycles of therapy. These initial toxicities, which led to more frequent and earlier drug discontinuations in the pracinostat group, likely limited the overall efficacy of the combination and may explain the negative clinical outcomes. This is in contrast to the earlier open-label study of pracinostat and azacitidine in MDS, in which toxicities were managed with adapted dose reductions, allowing patients to remain on therapy for longer periods.
In an attempt to determine whether excess toxicity was responsible for these results, we analyzed the outcomes of patients who received at least 4 cycles of therapy. Although no differences in terms of response were observed between the 2 groups, a tendency toward improved response duration and OS was observed in the pracinostat group. The observed differences were not significant, because this subgroup analysis did not have statistical power to demonstrate superiority of the combination. Therefore, further studies will be required to confirm these results. It is noteworthy that, although it involved a different patient population, a phase 2 trial of azacitidine and pracinostat in newly diagnosed elderly patients with AML who were not eligible to receive intensive induction chemotherapy because of comorbidities or unfavorable disease features demonstrated significant activity of the combination with CR rates of 42% and a 1-year OS rate of 60%; and it was associated with a lower rate of early discontinuation compared with our current study. 21 It is possible that older
Original Article patients with AML, who are debilitated from their disease and for whom alternative therapies are limited, may be more willing to comply with regimens associated with fatigue and gastrointestinal toxicities compared with patients with MDS, who are ambulatory and have more therapeutic options. Also, the absence of sequencing analysis limits our ability to determine whether unbalanced distribution of patients with high-risk mutational features, such as TP53 mutations [22] [23] [24] or TET2 mutations, associated with higher response rates to azacitidine, [24] [25] [26] may be partially responsible for the observed clinical outcomes. Previous studies suggested that achieving a response to azacitidine was associated with improved survival outcomes in patients with MDS. 27 However, the tendency to lower CR rates with azacitidine and pracinostat observed in our study did not correlate with shorter survival outcomes in the combination arm.
Although several preclinical and pilot clinical experiences have suggested a potential benefit of adding HDAC inhibitors to hypomethylating agents as combination epigenetic therapy, 12, 13 combination trials evaluating such treatment combinations with valproic acid, 14, 28 entinostat, 29 panobinostat, 30 and vorinostat have so far had challenges to significantly improve outcomes, mainly because of suboptimal HDAC inhibition potency, 31 suboptimal dosing, or excess toxicity in combination with azacitidine. 16, 32 For example, the Southwest Oncology Group S1117 study, 33 a randomized study of azacitidine with or without vorinostat in patients with MDS, produced results similar to those we report here, although with lower CR rates (15% vs 24%) and higher treatmentdiscontinuation rates because of AEs for combination therapy compared with azacitidine monotherapy (24% vs 9%). Although it was conducted in a different patient population, similar observations also were reported with azacitidine and vorinostat in patients with AML and MDS who had comorbidities, poor performance, or organ dysfunction 34 in whom the addition of vorinostat did not significantly impact OS. Therefore, we can speculate that the absence of clinical benefit in the current study and in previous studies could be explained in part by nonoptimal treatment schedules. Also, our study did not include methylation assays or other correlative studies before the initiation of therapy and during the course of treatment. We acknowledge that this is a limitation.
Pracinostat has demonstrated superior preclinical pharmacokinetic/pharmacodynamic properties compared with other HDAC inhibitors that have favorable best-inclass pharmacokinetic properties. 35, 36 In fact, as reported in the initial phase 1 study of pracinostat in patients with hematologic malignancies, 17 appropriate pracinostat exposure and HDAC inhibition is possible with doses as low as 40 mg daily. This suggests that alternative combination regimens with lower pracinostat daily doses or less frequent dosing may be better tolerated and should be investigated in the MDS setting, in which chronic tolerability is paramount.
In conclusion, the combination of pracinostat and azacitidine evaluated in this study did not improve the outcome of patients with MDS compared with azacitidine monotherapy. Excess toxicity in the form of cytopenias, fatigue, and gastrointestinal toxicity resulted in earlier discontinuations and suboptimal long-term exposure to treatment, potentially leading to reduced efficacy. Lower daily doses or alternative dosing schedules aimed at reducing treatment toxicity should be evaluated. 
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